ESR1 activating variants
Therapeutic response
Precision oncology relationships for therapeutic response involving this biomarker.
Organizations
Biomarkers
Cancer types
Therapies
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| EMA (1) FDA (2) | ER positive, ESR1 activating variants, HER2-negative | Invasive Breast Carcinoma | Elacestrant | |
| EMA (1) FDA (2) | ER positive, ESR1 activating variants, HER2-negative | Invasive Breast Carcinoma | Imlunestrant | |
| EMA (1) | ER positive, ESR1 activating variants, HER2-negative | Invasive Breast Carcinoma | Abemaciclib, Camizestrant | |
| EMA (1) | ER positive, ESR1 activating variants, HER2-negative | Invasive Breast Carcinoma | Camizestrant, Palbociclib | |
| EMA (1) | ER positive, ESR1 activating variants, HER2-negative | Invasive Breast Carcinoma | Camizestrant, Ribociclib |